Trends & Forecasts

Yvonne Duckworth lays out insights into Pharma 4.0 gleaned in a recent report by CRB. VR, AR, AI: is it more than just alphabet soup?

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

A report from Clarivate has tipped 7 drugs for potential blockbuster status in 2022. Here’s what makes them stand out.

In this new series, we ask industry leaders in the cell and gene field to answer key questions about the industry.

As the fires of the American opioid crisis continue to burn, can new painkillers step in?

2022 is well underway, and with it comes The Medicine Maker Company of the Year Awards. Our old faithful Power List is back too.

Can digital approaches help improve pharmacovigilance practices?

A virtual meeting held by the UK Cell and Gene Catapult shared a year of progress, and thoughts on the challenges that lie ahead for British ATMPs.

Edd Stone of The Technology Partnership outlines current challenges in the cell and gene field - and what we can do about them.

How can the NLRP3 inflammasome can be exploited to slow the decline associated with Alzheimer's disease?